CBUS
Cibus·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
High Gross Profit Margin
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CBUS
Cibus Inc.
A biotechnology company with gene editing technology
6455 Nancy Ridge Drive, San Diego, CA 92121
--
Cibus Inc., incorporated in Delaware on January 8, 2010, is a wholly owned subsidiary of Cellectis S.A. The company is a consumer-centric, food and agriculture-focused company. By combining its key gene editing technology and technical expertise with its innovative business strategy, the company is pioneering an optimization shift to provide healthier food ingredients to consumers and agriculturally beneficial features to farmers. The company is developing and developing specialty food ingredients such as healthy oil and high-fiber wheat, as well as food crops with desirable traits such as herbicide tolerance. While the characteristics that realize these characteristics may occur in traditional natural and random ways, or in controlled environments through traditional agricultural techniques, these processes are imprecise and take decades or even decades. Their technology enables them to edit plant genomes precisely and concretely to produce the desired features and properties, resulting in a final product without foreign DNA. The company believes that the accuracy, specificity, cost-effectiveness and speed of development of gene editing technologies will enable them to provide meaningful disruption to the food and agricultural industries.
Earnings Call
Q2/2025
Estimate EPS-0.33
Actual EPS-0.61
Estimate Revenue1.15M
Actual Revenue933.00K
Cibus' Q2 2025: Navigating Contradictions in EU Regulations and Biofragrance Revenue
Aug 15,2025 01:25
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CBUS has released its 2025 Q3 earnings. EPS was reported at -0.44, versus the expected -0.18, missing expectations. The chart below visualizes how CBUS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CBUS has released its 2025 Q3 earnings report, with revenue of 615.00K, reflecting a YoY change of -63.11%, and net profit of -24.30M, showing a YoY change of 87.94%. The Sankey diagram below clearly presents CBUS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
